Conventional and complementary therapies: a tale of two research standards?
Levine
Mark N
MN
D015670:Acupuncture Therapy; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic / Q000592:standards*; D000529:Complementary Therapies / Q000009:adverse effects; D003511:Cyclohexanols / Q000627:therapeutic use*; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D019587:Dietary Supplements; D019317:Evidence-Based Medicine / Q000592:standards; D019584:Hot Flashes / Q000188:drug therapy / Q000628:therapy*; D006801:Humans; D009369:Neoplasms / Q000178:diet therapy / Q000188:drug therapy / Q000401:mortality / Q000628:therapy*; D010447:Peptide Hydrolases / Q000627:therapeutic use; D018570:Risk Assessment; D013997:Time Factors; D016896:Treatment Outcome; D000069470:Venlafaxine Hydrochloride; D000093542:Gemcitabine
D000964:Antimetabolites, Antineoplastic; D003511:Cyclohexanols; D003841:Deoxycytidine; D000069470:Venlafaxine Hydrochloride; D010447:Peptide Hydrolases; D000093542:Gemcitabine